Full Press Release Details
dupixent dupilumab approved in the european union as the first and only medicine for young children with eosinophilic esophagitis.
REGN
dupixent dupilumab approved in the european union as the first and only medicine for young children with eosinophilic esophagitis
Key Takeaway: dupixent dupilumab approved in the european union as the first and only medicine for young children with eosinophilic esophagitis